GENERAL ELECTRIC CO (GE) Stock News

A securities class action lawsuit has been filed against Badger Meter, Inc. (NYSE: BMI) alleging that the company made materially false and misleading statements about its financial results and growth prospects during the Class Period (April 18, 2024 - April 16, 2026). The lawsuit claims Badger Meter artificially inflated results by pulling forward customer orders to recognize revenue early, concealing weakening demand and deteriorating order trends. The lead plaintiff deadline is August 3, 2026.

GE Vernova and PPL represent two distinct approaches to capitalizing on the AI power boom and clean energy transition. GE Vernova is a technology powerhouse supplying turbines and electrical equipment with strong growth metrics, while PPL is a regulated utility offering steady dividend income. The article recommends GE Vernova for growth-focused investors seeking exposure to AI infrastructure, while PPL suits income-focused investors seeking predictable returns.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Chevron has partnered with GE Vernova to develop 4 gigawatt-hours of behind-the-meter natural gas power for AI data centers through 'power foundries' across the U.S. Chevron will leverage its Permian Basin natural gas production to fuel GE Vernova's gas turbines, with deliveries expected to begin in late 2027 or early 2028. While the partnership addresses surging data center energy demands, environmental concerns persist despite plans to integrate carbon capture technology.

GE Aerospace and StandardAero both benefit from growing aerospace demand but operate at different stages of the aircraft lifecycle. GE Aerospace manufactures engines with a massive installed base and strong profitability (19% net margin), while StandardAero provides maintenance and repair services with lower valuation but higher risk due to customer concentration and internal control issues. The author favors GE Aerospace for conservative investors despite its higher valuation, citing its scale, history, and stability.

GE Vernova and Vistra are competing in the AI data center power boom, but their business models differ significantly. GE Vernova manufactures turbines for on-site power generation with a $263 billion backlog and strong margins, while Vistra operates a massive generation fleet and retail utility business with higher leverage. The author favors GE Vernova due to its clearer growth path independent of commodity price fluctuations.

A comprehensive patent landscape analysis of 50,011 energy optimization patents filed from 2010-2025 reveals China leading with 40,878 patents, followed by the U.S. with 4,484. The Energy Management Systems market is projected to grow from USD 53.26 billion in 2024 to USD 111.86 billion by 2030, with Asia-Pacific as the fastest-growing region. Key innovations include HVAC control, energy storage, and smart grid technologies.

Aimei Health Technology Co., Ltd. announced the termination of its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, due to failure to close the transaction by the outside date specified in the agreement. The company expressed confidence in identifying future transaction opportunities.

Amerant Investments announced the appointment of Ricardo Sucre as Head of International Wealth Management Business Development. Sucre brings over 20 years of experience from leading financial institutions including Morgan Stanley and Bolton Global Capital. The appointment reflects Amerant's strategic focus on expanding its international wealth management platform and attracting experienced financial advisors to its integrated banking and investment services model.

Wiztrust has launched Blueprint GEO, a solution developed with GetMint to help organizations manage their visibility in large language models. Eight major companies including Capgemini, BPCE, Gecina, Malakoff Humanis, and Macif have adopted the platform. The solution measures the gap between how AI portrays a brand versus desired positioning, then adjusts PR strategy accordingly. Wiztrust clients achieve 77.3/100 visibility scores, 31% higher than the market average of 58.8/100.

Electrification secured $2.4 billion in data center equipment orders during the first quarter of 2026, beating the segment's total for all of 2025.

GE Vernova stock rose 21.3% in June driven by increased AI infrastructure spending announcements from major hyperscalers. Oracle announced plans to increase capital spending to $90-95 billion in fiscal 2027, while Alphabet announced an $80 billion equity raise for AI infrastructure. These developments support higher long-term earnings forecasts for GE Vernova's gas turbines and electrification equipment used in AI data centers. The company's $163 billion backlog is expected to reach $200 billion by 2027.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting competing offers.

The article compares AST SpaceMobile, a pre-revenue satellite broadband startup, against GE Aerospace, an established aviation engine manufacturer. While AST SpaceMobile shows impressive revenue growth of 1,505% in FY2025, it remains deeply unprofitable with a net loss of $341.9 million and negative free cash flow of $1.1 billion. GE Aerospace demonstrates strong fundamentals with $45.9 billion in revenue, $8.7 billion in net income, and $7.3 billion in free cash flow. The author recommends GE Aerospace for 2026, citing its proven business model, strong execution, and cash generation versus AST SpaceMobile's speculative technology and execution risks.

GE Vernova shares fell 7.4% amid a broad-based sell-off in AI data center stocks triggered by South Korean regulatory concerns about leveraged funds tracking semiconductor companies. Despite the decline, the company's fundamentals remain strong with continued backlog growth and slot reservation agreements extending to 2031. The sell-off reflects profit-taking in a sector that has surged over the past year rather than fundamental concerns about AI investment demand.

GENFIT announced positive Phase 1b results for GNS561, an investigational drug targeting autophagy, in combination with a MEK inhibitor for treating advanced KRAS-mutated cholangiocarcinoma. The study of 19 patients showed a favorable safety profile with no dose-limiting toxicities and early signs of antitumor activity, with approximately half achieving stable disease. Phase 2 initiation is planned for the second half of 2026.

GENFIT reported positive Phase 1b results for GNS561 combined with a MEK inhibitor in heavily pretreated cholangiocarcinoma patients with KRAS mutations. The drug demonstrated favorable safety and tolerability profiles with no dose-limiting toxicities, along with early signs of antitumor activity. Approximately half of the 19 patients achieved stable disease at Week 6, with one patient maintaining this status through Week 30. The company plans to extend Phase 1b with additional cohorts at higher doses and proceed to Phase 2 launch in H2 2026.

Rep. Ro Khanna, D-Calif., has been a critic of the Elon-Musk-led Department of Government Efficiency cuts.

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

Both American Electric Power and GE Vernova are benefiting from unprecedented demand driven by the AI data center boom. AEP operates the largest U.S. electric transmission system with steady 11% rate base growth projected through 2030, while GE Vernova is a global power generation leader with a massive $163 billion backlog expected to reach $200 billion by 2027. Despite AEP's conservative valuation and stable dividend, the analyst recommends GE Vernova due to its superior growth trajectory and record free cash flow generation.

Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.

GE Vernova, spun off from General Electric two years ago, has surged nearly 750% since its market debut. The company operates in Power, Electrification, and Wind segments and is positioned to benefit from the 'AI grid supercycle' driven by hyperscalers and AI infrastructure providers. With a $163 billion backlog and projected revenue growth of 16% CAGR through 2028, analysts view the stock as fairly valued at 36x earnings despite its strong growth prospects.

InnSuites Hospitality Trust (IHT) reported Fiscal Q1 2027 net income of $74,702, a $35,672 improvement year-over-year, with record hotel revenue of $2.2 million and combined occupancy reaching 85.37%. The company continues exploring diversification opportunities including a potential reverse merger, IBC Hotels independent hotel services, and investments in UniGen Power's clean energy technology.

Rosen Law Firm is reminding investors in Regencell Bioscience Holdings Limited (RGC) and AeroVironment, Inc. (AVAV) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and financial exposure during their respective class periods.

GE Vernova shares rose up to 6.5% following a U.S.-Iran memorandum of understanding that aims to reduce regional uncertainty. The deal includes a $300 billion reconstruction fund for Iran, which could drive equipment orders for GE Vernova's gas turbines, electrification equipment, and wind turbines. The company's strong order book and long-term service contracts position it well to benefit from potential Iranian infrastructure rebuilding projects.

BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. Phase 1 results showed BGE-102 achieved median hsCRP reductions of 86% and was well tolerated. Topline data are anticipated in the second half of 2026, with an additional Phase 1b/2a trial in diabetic macular edema planned for mid-2026.

Aurion Resources Ltd. has successfully completed its plan of arrangement with Agnico Eagle Mines Limited, whereby Agnico acquired all outstanding common shares of Aurion for C$2.60 per share in cash. Following the completion, Aurion Shares will be delisted from the TSX Venture Exchange and Aurion will cease to be a reporting issuer under Canadian securities laws.

Vertex Pharmaceuticals reported positive Phase 3 clinical data for CASGEVY in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. All evaluated patients achieved primary endpoints with sustained clinical benefits and a consistent safety profile. The company is pursuing FDA approval to expand the therapy's use to younger children.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) reported new clinical data showing that CASGEVY (exagamglogene autotemcel) delivered efficacy and safety outcomes in children ages 5 to 11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) The data were consistent with results previously observed in adolescent and adult patients. Phase 3 Studies Show High Rates Of Clinical Response An interim analysis from the Phase 3 CLIMB-151 study in children with severe SCD showed all 11 treated patients remained free from vaso-occlusive crises (VOCs). data-variant="card" data-news-mode="manual" > Read Also: Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps Among the eight patients with sufficient follow-up, 100% achieved the primary endpoint of remaining VOC-free for at least 12 ... Full story available on Benzinga.com

Aurion Resources Ltd. has obtained final court approval for its plan of arrangement with Agnico Eagle Mines Limited. Under the deal, Agnico will acquire all outstanding Aurion shares for C$2.60 per share in cash. The arrangement was approved by shareholders and warrantholders on June 5, 2026, and is expected to close on or about June 15, 2026, pending TSX Venture Exchange approval and satisfaction of customary closing conditions.